Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Jul 28, 2025

Suryoday SFB— Well-Positioned For A Valuation Multiple Re-Rating, Says Centrum Post Q1 Result; Maintains 'Buy'

Suryoday SFB— Well-Positioned For A Valuation Multiple Re-Rating, Says Centrum Post Q1 Result; Maintains 'Buy'
 (Photo: Usha Kunji/NDTV Profit)
STOCKS IN THIS STORY
Suryoday Small Finance Bank Ltd
--

Suryoday SFB's beat on operating expenses was encouraging, especially in light of strong sequential growth in the loan and deposit book. However, slippages were higher than anticipated, and the management has guided for a recovery trajectory skewed towards the second half of the fiscal year.

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Centrum Broking Report

Suryoday Small Finance Bank Ltd. has delivered a resilient set of numbers despite a challenging macro backdrop. While net interest margin compression was visible—mirroring trends across the sector—it remained within our expectations.

Notably, the beat on operating expenses was encouraging, especially in light of strong sequential growth in the loan and deposit book. However, slippages were higher than anticipated, and the management has guided for a recovery trajectory skewed towards the second half of the fiscal year.

Accordingly, we have revised our provisioning estimates upwards. That said, stress in asset quality has been a sectorwide phenomenon, and commentary from peers remains constructive on improving credit metrics going forward.

We view Suryoday as a compelling investment proposition on multiple fronts-

  1. Attractive Valuation: Assigning a just 0.8x our FY28E adjusted book value, the stock offers a significant upside potential. With RoE expected to improve to 13% by FY27, we see an attractive ~35% upside from current levels;

  2. CGFMU Cover: The reported PCR of 35% appears optically low due to timing differences of CGFMU claim.

We expect this to normalize as Suryoday starts receiving CGFMU claim recoveries (notably, a ~Rs 2.5 billion inflow anticipated in H2FY26), which implies that the actual uncovered NPAs are minimal. Rolling forward our estimates to H1 FY28E, we revise our target price to Rs 178 and maintain a Buy rating.

We believe the stock is well-positioned for a valuation multiple re-rating as operational performance continues to strengthen

Click on the attachment to read the full report:

Centrum Suryoday_Small_Finance_Bank_Q1FY26_Result_Update_.pdf

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search